Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
1.
Clin Psychopharmacol Neurosci ; 13(1): 109-12, 2015 Apr 30.
Artículo en Inglés | MEDLINE | ID: mdl-25912544

RESUMEN

Clozapine has been demonstrated to be useful for treating refractory schizophrenia. However, hypersalivation occurs in 31.0- 97.4% of the patients treated with clozapine. Accordingly, some patients who are disturbed by their hypersalivation refuse to continue with clozapine treatment. This study investigated the efficacy of the anticholinergic agent scopolamine butylbromide against clozapine-induced hypersalivation. Five schizophrenia patients were coadministered scopolamine butylbromide (30-60 mg/ day) for 4 weeks. At the baseline and after 4 weeks' treatment, we subjectively evaluated hypersalivation using a visual analog scale and objectively assessed it using the Drooling Severity Scale and Drooling Frequency Scale. As a result, improvements in the patients' Drooling Severity Scale and Drooling Frequency Scale scores, but no improvements in their visual analog scale scores, were observed after scopolamine butylbromide treatment. These results indicate that at least some schizophrenic patients with clozapine-induced hypersalivation would benefit from scopolamine butylbromide treatment. We conclude that clozapine-induced hypersalivation is one factor of stress to patients. Subjective hypersalivation was not improved, but objective hypersalivation was, by scopolamine butylbromide treatment. However, scopolamine butylbromide and clozapine possess anticholinergic effects so clinicians should closely monitor patients who take scopolamine butylbromide.

2.
Asian J Psychiatr ; 6(3): 200-7, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23642976

RESUMEN

Japan approved clozapine for treatment-resistant schizophrenia in June 2009. The aim of this study was to evaluate clozapine's efficacy and tolerability in Japanese patients. A twelve-week, single-arm clinical trial of clozapine in treatment-resistant schizophrenia inpatients, was conducted under real-world conditions using raters masked for type of antipsychotic. Thirty-eight patients were recruited, with 33 (86.8%) completing the trial. At week 12, clozapine was associated with significant improvement in the Positive and Negative Syndrome Scale (PANSS) total (p < 0.0001), PANSS positive (p < 0.0001), negative (p = 0.0055) and general subscale scores (p < 0.0001). Significant improvements occurred in all PANSS scores by week 4, the first post-baseline psychopathology rating. Altogether, 50.0% of patients showed ≥20% reduction in PANSS total score, 20.6% had ≥30% reduction and 14.7% had >40% reduction. Eighteen patients (47.4%) were discharged before week 12. However, all patients experienced ≥1 adverse event. Two of 38 patients (5.2%) dropped out due to moderate leucopenia and one of them developed agranulocytosis after stopping clozapine. However, both patients recovered. Eight adverse events (hypersalivation, fatigue, sedation, constipation, insomnia, nausea/vomiting, chest pain and leucopenia) were observed in 34-79% of patients. These findings suggest that clozapine is beneficial in Japanese treatment-resistant schizophrenia patients. However, attention should be paid to patients' adverse events.


Asunto(s)
Antipsicóticos/administración & dosificación , Clozapina/administración & dosificación , Esquizofrenia/tratamiento farmacológico , Antipsicóticos/efectos adversos , Clozapina/efectos adversos , Esquema de Medicación , Resistencia a Medicamentos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento
3.
Psychiatr Genet ; 23(3): 117-23, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23474461

RESUMEN

OBJECTIVES: To search for schizophrenia susceptibility loci, we carried out a case-control study using 28601 microsatellite markers distributed across the entire genome. MATERIALS AND METHODS: To control the highly multiple testing, we designed three sequential steps of screening using three independent sets of pooled samples, followed by the confirmatory step using an independent sample set (>2200 case-control pairs). RESULTS: The first screening using pooled samples of 157 case-control pairs showed 2966 markers to be significantly associated with the disorder (P<0.05). After the second and the third screening steps using pooled samples of 150 pairs each, 374 markers remained significantly associated with the disorder. We individually genotyped all screening samples using a total of 1536 tag single nucleotide polymorphisms (SNPs) located in the vicinity of ~200 kb from the 59 positive microsatellite markers. Of the 167 SNPs that replicated the significance, we selected 31 SNPs on the basis of the levels of P values for the confirmatory association test using an independent-sample set. The best association signal was observed in rs13404754, located in the upstream region of SLC23A3. We genotyped six additional SNPs in the vicinity of rs13404754. Significant associations were observed in rs13404754, rs6436122, and rs1043160 in the cumulative samples (2617 cases and 2698 controls) (P=0.005, 0.035, and 0.011, respectively). These SNPs are located in the linkage disequilibrium block of 20 kb in size containing SLC23A3, CNPPD1, and FAM134A genes. CONCLUSION: Genome-wide association study using microsatellite markers suggested SLC23A3, CNPPD1, and FAM134A genes as candidates for schizophrenia susceptibility in the Japanese population.


Asunto(s)
Marcadores Genéticos , Estudio de Asociación del Genoma Completo , Repeticiones de Microsatélite/genética , Esquizofrenia/genética , Adulto , Estudios de Casos y Controles , Femenino , Humanos , Japón , Masculino , Persona de Mediana Edad , Polimorfismo de Nucleótido Simple
5.
BMJ Open ; 2(3)2012.
Artículo en Inglés | MEDLINE | ID: mdl-22566608

RESUMEN

OBJECTIVES: The present study aimed to validate screening tools that could be used to identify depression among workers. DESIGN: Diagnostic test study. SETTINGS: Workers from three Japanese companies agreed to participate. PARTICIPANTS: Recruitment for the group 1 occurred between January 2001 and February 2004, and 89 participants (81 men and 8 women with a mean age of 38.4±6.6 years) (98.8%) took part in the study. Recruitment for the group 2 occurred between July 2000 and February 2004, and 1500 participants (1408 men and 92 women with a mean age of 40.9±7.2 years) (94.2%) took part in the study. Demographic data are shown in supplementary table 1. PRIMARY AND SECONDARY OUTCOME MEASURES: the Beck Depression Inventory (BDI) and a two-question case-finding instrument (TQI) were administered to 89 workers and Mini-International Neuropsychiatric Interview was conducted to verify the diagnosis of depression. A second group of 1500 workers completed the BDI and TQI to detect possible sample bias for the distribution of depression. Specificity, sensitivity and positive predictive value were calculated in order to obtain the optimal cut-off scores for BDI and TQI and receiver operating characteristic curves, and Youden Index were applied to further refine the optimal cut-off scores. RESULTS: When paired together, BDI score ≥10 and TQI score of 2 adequately identified workers who had major depressive disorder and those who had other psychiatric disorders that are frequently comorbid with major depressive disorder. CONCLUSIONS: The combination of BDI score ≥10 and TQI score of 2 can adequately screen for current and potential cases of depression among workers. Furthermore, BDI and TQI offer the advantage of being relatively easy to administer to a large number of workers. Early detection of depression could improve treatment outcomes and decrease economic burden. TRIAL REGISTRATION: [corrected]

6.
Psychiatry Clin Neurosci ; 64(3): 268-73, 2010 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20602727

RESUMEN

AIMS: The aim of this study was to analyze the relation between treatment response and the duration of untreated illness (DUI) in 133 outpatients with the first major depressive disorder (MDD) episode. METHODS: A logistic regression was performed with DUI, sex, age at onset, and score for 17 items on the Hamilton Depression Rating Scale at the time of start of fluvoxamine treatment as the explanatory variables, and the response and the remission as the outcome variables. RESULTS: Regression analysis showed significant association between the response and DUI (P < 0.0001), and between the remission and DUI (P < 0.0001), respectively. The remission rate gradually decreased with longer DUI. CONCLUSION: Early treatment of first depressive episodes is important because a shorter DUI implied better remission outcomes.


Asunto(s)
Edad de Inicio , Antidepresivos/uso terapéutico , Trastorno Depresivo Mayor/tratamiento farmacológico , Fluvoxamina/uso terapéutico , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores de Tiempo , Resultado del Tratamiento
7.
World J Biol Psychiatry ; 11(2 Pt 2): 431-8, 2010 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-19353385

RESUMEN

Schizophrenia is a common psychiatric disorder characterized by disturbances of cognition, emotion and social functioning. There are few studies investigating a possible genetic basis for the underlying mechanism of cognitive dysfunctions. A genetic variation in the dysbindin gene (DTNBP1: dystrobrevin binding protein 1), a susceptibility gene for schizophrenia, has been reported to be associated with general cognitive ability and cognitive decline in patients with schizophrenia. Although profound disturbances of memory performance are observed in schizophrenia, only one study has reported a relationship between this gene and spatial working memory in a Caucasian population. We examined a possible association between a protective haplotype of DTNBP1 for developing schizophrenia and memory performance measured by the Wechsler Memory Scale-Revised (WMS-R) and the Wechsler Adult Intelligence Scale-Revised (WAIS-R) in 165 healthy volunteers and 70 patients with schizophrenia in a Japanese population. Healthy controls that carry the protective haplotype showed higher performance in several memory domains measured by the WMS-R than those who did not. Genotype effect on memory performance was not observed in patients with schizophrenia. This haplotype did not affect IQ and its sub-scores as measured by the Wechsler Adult Intelligence Scale-Revised in both groups. These data suggest that DTNBP1 may have impact on parts of memory functions.


Asunto(s)
Proteínas Portadoras/genética , Memoria/fisiología , Polimorfismo de Nucleótido Simple/genética , Adulto , Disbindina , Proteínas Asociadas a la Distrofina , Femenino , Genotipo , Haplotipos , Humanos , Masculino , Persona de Mediana Edad , Esquizofrenia/genética , Psicología del Esquizofrénico , Escalas de Wechsler
8.
Int J Neuropsychopharmacol ; 11(2): 261-7, 2008 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-17697394

RESUMEN

Selective serotonin reuptake inhibitor (SSRI)-induced nausea can be severe enough to lead to early treatment discontinuation. However, it is currently not possible to predict the occurrence of nausea before the initiation of SSRI treatment. In this study, we investigated the effect of genetic polymorphisms in the 5-hydroxytryptamine type 2A, 3A, and 3B (5-HT3B) receptors, 5-HT transporter, and CYP2D6 genes on the incidence of paroxetine-induced nausea. A consecutive series of 72 Japanese patients with depressive or anxiety disorders were treated with paroxetine. Paroxetine-induced nausea was assessed by a pharmacist and was observed in 29.2% of the patients. A significant (nominal p=0.00286) association was found between the incidence of nausea and the -100_-102AAG insertion/deletion polymorphism of the 5-HT3B receptor gene. No significant associations were observed between the other genetic polymorphisms and the incidence of nausea. The -100_-102AAG deletion variant of the 5-HT3B receptor gene may affect paroxetine-induced nausea.


Asunto(s)
Antidepresivos de Segunda Generación/efectos adversos , Trastornos de Ansiedad/tratamiento farmacológico , Trastorno Depresivo/tratamiento farmacológico , Náusea/etiología , Paroxetina/efectos adversos , Polimorfismo Genético , Receptores de Serotonina 5-HT3/genética , Inhibidores Selectivos de la Recaptación de Serotonina/efectos adversos , Adolescente , Adulto , Anciano , Antidepresivos de Segunda Generación/sangre , Trastornos de Ansiedad/genética , Trastorno Depresivo/genética , Femenino , Predisposición Genética a la Enfermedad , Humanos , Incidencia , Japón , Masculino , Persona de Mediana Edad , Náusea/inducido químicamente , Náusea/genética , Paroxetina/sangre , Factores de Riesgo , Inhibidores Selectivos de la Recaptación de Serotonina/sangre , Índice de Severidad de la Enfermedad
9.
Prog Neuropsychopharmacol Biol Psychiatry ; 32(1): 204-8, 2008 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-17822820

RESUMEN

Lithium is one of the most commonly used drugs for the treatment of bipolar disorder. To prescribe lithium appropriately to patients, predictors of response to this drug were explored, and several genetic markers are considered to be good candidates. We previously reported a significant association between genetic variations in the breakpoint cluster region (BCR) gene and bipolar disorder. In this study, we examined a possible relationship between response to maintenance treatment of lithium and Asn796Ser single-nucleotide polymorphism in the BCR gene. Genotyping was performed in 161 bipolar patients who had been taking lithium for at least 1 year, and they were classified into responders for lithium mono-therapy and non-responders. We found that the allele frequency of Ser796 was significantly higher in non-responders than in responders. Further investigation is warranted to confirm our findings.


Asunto(s)
Antimaníacos/uso terapéutico , Trastorno Bipolar/genética , Trastorno Bipolar/prevención & control , Compuestos de Litio/uso terapéutico , Mutación Missense/genética , Polimorfismo de Nucleótido Simple/genética , Proteínas Proto-Oncogénicas c-bcr/genética , Adulto , Análisis de Varianza , Asparagina/genética , Trastorno Bipolar/clasificación , Escalas de Valoración Psiquiátrica Breve , Femenino , Frecuencia de los Genes , Genotipo , Humanos , Masculino , Persona de Mediana Edad , Farmacogenética , Serina/genética
10.
Am J Med Genet B Neuropsychiatr Genet ; 147B(4): 531-4, 2008 Jun 05.
Artículo en Inglés | MEDLINE | ID: mdl-18085546

RESUMEN

Altered dopamine D2 receptor (D2R) is hypothesized to be a susceptibility factor for major psychosis. Recent studies showed that a new intracellular protein, prostate apoptosis response 4 (Par-4), plays a critical role in D2R signaling. We conducted a genetic association analysis between Par-4 gene (PAWR) and schizophrenia and mood disorders in a Japanese population (schizophrenia: 556 cases, bipolar disorder (BP): 150 cases, major depressive disorder (MDD): 312 cases and 466 controls). Applying the recommended 'gene-based' association analysis, we selected five tagging SNPs in PAWR from the HapMap database. No significant association was obtained found with schizophrenia or MDD or BP. We found a significant association of one tagging SNP with BP in a genotype-wise analysis (P = 0.0396); however, this might be resulted from type I error due to multiple testing (P = 0.158 after SNPSpD correction). Considering the size of our sample and strategy, our results suggest that the PAWR does not play a major role in schizophrenia or mood disorders in the Japanese population.


Asunto(s)
Proteínas Reguladoras de la Apoptosis/genética , Trastornos del Humor/genética , Esquizofrenia/genética , Adulto , Pueblo Asiatico/genética , Trastorno Bipolar , Estudios de Casos y Controles , Trastorno Depresivo Mayor , Femenino , Predisposición Genética a la Enfermedad , Humanos , Desequilibrio de Ligamiento , Masculino , Persona de Mediana Edad , Polimorfismo de Nucleótido Simple
11.
Psychiatr Genet ; 17(4): 227-31, 2007 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-17621166

RESUMEN

BACKGROUND: Microarray studies of schizophrenic brains revealed decreases in the expression of myelin and oligodendrocyte-related genes. Of these genes, sex-determining region Y-box 10 (SOX10) is a major transcription factor modulating the expression of proteins involved in neurogenesis and myelination. The SOX10 gene is located on chromosome 22q13.1, a region repeatedly reported to show positive signals in linkage studies on schizophrenia. OBJECTIVE: This study was conducted to clarify the exact role of SOX10 in the pathophysiology of schizophrenia. METHODS: We performed an association analysis of SOX10 in a Japanese population of 915 schizophrenic patients and 927 controls. Genotyping was carried out using polymerase chain reaction restriction fragment length polymorphism. MAIN RESULTS: One single nucleotide polymorphism of the SOX10 gene (rs139,887) was selected as a haplotype tag single nucleotide polymorphism using 96 controls. A significant association was observed in the genotype and allelic frequency of this single nucleotide polymorphism between schizophrenic patients and controls (P=0.025 and P=0.009, respectively). Especially, a significant association was found in male patients, but not female patients. We also performed a mutational search of the whole coding region, branch site, and promoter region of SOX10 in 96 schizophrenic patients, but no potential functional polymorphisms were detected. CONCLUSION: This study suggests that the SOX10 gene is related to the development of schizophrenia in the Japanese population.


Asunto(s)
Proteínas de Unión al ADN/genética , Proteínas del Grupo de Alta Movilidad/genética , Esquizofrenia/genética , Factores de Transcripción/genética , Adulto , Anciano , Mapeo Cromosómico , Cromosomas Humanos Par 22 , Cartilla de ADN , Femenino , Predisposición Genética a la Enfermedad , Genotipo , Humanos , Japón , Masculino , Persona de Mediana Edad , Mutación , Análisis de Secuencia por Matrices de Oligonucleótidos , Valores de Referencia , Factores de Transcripción SOXE
12.
Schizophr Res ; 91(1-3): 22-6, 2007 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-17303389

RESUMEN

Postmortem studies regarding schizophrenia revealed altered expression of genes related to gamma-amino butyric acid neurotransmission system. One of the most consistent findings is the reduced level of 67 kDa glutamic acid decarboxylase isoform (GAD(67)). Moreover, several studies reported positive associations between the GAD(67) gene (GAD1) and schizophrenia. These reasons, motivated us to carry out replication study regarding association between GAD1 (fourteen tagging SNPs) and schizophrenia in Japanese population (562 schizophrenic patients and 470 controls). However we couldn't confirm significant association that had been previously reported. Considering size of our sample and strategy that corresponds well with the approaches used in gene-based association analysis, our conclusion is that GAD1 does not play a major role in schizophrenia in Japanese population.


Asunto(s)
Pueblo Asiatico/genética , Pueblo Asiatico/estadística & datos numéricos , Expresión Génica/genética , Glutamato Descarboxilasa/genética , Glutamato Descarboxilasa/metabolismo , Isoenzimas/genética , Isoenzimas/metabolismo , Esquizofrenia/etnología , Esquizofrenia/genética , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Marcadores Genéticos , Genotipo , Haplotipos/genética , Humanos , Japón , Desequilibrio de Ligamiento/genética , Masculino , Persona de Mediana Edad , Polimorfismo de Nucleótido Simple/genética , Ácido gamma-Aminobutírico/metabolismo
13.
Brain Res ; 1125(1): 85-93, 2006 Dec 13.
Artículo en Inglés | MEDLINE | ID: mdl-17113049

RESUMEN

We investigated the relationship between temperamental predisposition and brain structure by using a standard questionnaire and high-resolution T1-weighted magnetic resonance image (MRI) in normal young volunteers. Fifty-six subjects completed the Japanese version of the Temperament and Character Inventory (TCI, 125 items) and underwent an MRI acquisition of the brain. The gray matter (GM) was extracted from the whole brain image of the subjects and normalized to the standard brain template using statistical parametric mapping and the optimized voxel-based morphometry (VBM) method. When the score on the harm avoidance (HA) subscale was used as a dependent variable, the multiple regression analysis revealed that the HA score positively correlated with the volume of the part of left amygdala. The region-of-interest analysis showed that the correlation was significant in the female subjects but not in the male subjects. The correlation was significant even after the effects of age, depression score, and total GM volume were taken into account. The differential correlation between the sexes may be caused by differences in hormonal condition and the vulnerability of women to socio-psychological stress. In addition, the novelty seeking (NS) score positively correlated with the GM of the left middle frontal gyrus. The volume of the tail of the right caudate nucleus positively correlated with the reward dependence (RD) score. With regard to the NS and RD scores, no significant sex difference was observed in the correlation. These results indicate that the temperamental traits measured using the questionnaire may have a morphological basis in the human brain.


Asunto(s)
Amígdala del Cerebelo/anatomía & histología , Amígdala del Cerebelo/fisiología , Reducción del Daño/fisiología , Imagen por Resonancia Magnética , Caracteres Sexuales , Temperamento/fisiología , Adulto , Pesos y Medidas Corporales , Mapeo Encefálico , Femenino , Lateralidad Funcional/fisiología , Humanos , Procesamiento de Imagen Asistido por Computador/métodos , Masculino , Inventario de Personalidad , Valor Predictivo de las Pruebas
14.
Schizophr Res ; 88(1-3): 245-50, 2006 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17010574

RESUMEN

Several lines of evidence suggest that disturbance of myelin-related genes is associated with the etiology of schizophrenia. Recently, the 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP) gene and the oligodendrocyte lineage transcription factor 2 (OLIG2) gene were reported to be related to the development of schizophrenia, based on the results of genetic association and microarray studies. In the present study, no significant association with schizophrenia was observed by single-marker or haplotype analysis for 6 tag SNPs of these genes (759 cases, 757 controls). These findings suggest that CNP and OLIG2 are unlikely to be related to the development of schizophrenia in the Japanese population.


Asunto(s)
2',3'-Nucleótido Cíclico Fosfodiesterasas/genética , Pueblo Asiatico/genética , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/genética , Proteínas del Tejido Nervioso/genética , Esquizofrenia/etnología , Esquizofrenia/genética , Adulto , Femenino , Genotipo , Humanos , Desequilibrio de Ligamiento/genética , Masculino , Persona de Mediana Edad , Vaina de Mielina/genética , Factor de Transcripción 2 de los Oligodendrocitos , Análisis de Secuencia por Matrices de Oligonucleótidos/métodos , Reacción en Cadena de la Polimerasa
15.
Hum Mol Genet ; 15(20): 3024-33, 2006 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-16959794

RESUMEN

Disrupted-in-schizophrenia 1 (DISC1), identified in a pedigree with a familial psychosis with the chromosome translocation (1:11), is a putative susceptibility gene for psychoses such as schizophrenia and bipolar disorder. Although there are a number of patients with major depressive disorder (MDD) in the family members with the chromosome translocation, the possible association with MDD has not yet been studied. We therefore performed an association study of the DISC1 gene with MDD and schizophrenia. We found that Cys704 allele of the Ser704Cys single-nucleotide polymorphism (SNP) was associated with an increased risk of developing MDD (P=0.005, odds ratio=1.46) and stronger evidence for association in a multi-marker haplotype analysis containing this SNP (P=0.002). We also explored possible impact of Ser704Cys on brain morphology in healthy volunteers using MR imaging. We found a reduction in gray matter volume in cingulate cortex and a decreased fractional anisotropy in prefrontal white matter of individuals carrying the Cys704 allele compared with Ser/Ser704 subjects. In primary neuronal culture, knockdown of endogenous DISC1 protein by small interfering RNA resulted in the suppression of phosphorylation of ERK and Akt, whose signaling pathways are implicated in MDD. When effects of sDISC1 (Ser704) and cDISC1 (Cys704) proteins were examined separately, phosphorylation of ERK was greater in sDISC1 compared with cDISC1. A possible biological mechanism of MDD might be implicated by these convergent data that Cys704 DISC1 is associated with the lower biological activity on ERK signaling, reduced brain gray matter volume and an increased risk for MDD.


Asunto(s)
Encéfalo/patología , Trastorno Depresivo Mayor/genética , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Sistema de Señalización de MAP Quinasas , Proteínas del Tejido Nervioso/genética , Polimorfismo de Nucleótido Simple , Adulto , Sustitución de Aminoácidos , Animales , Estudios de Casos y Controles , Trastorno Depresivo Mayor/sangre , Femenino , Proteínas Fluorescentes Verdes , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , ARN Interferente Pequeño/genética , Ratas , Transfección
16.
Am J Med Genet B Neuropsychiatr Genet ; 141B(8): 929-34, 2006 Dec 05.
Artículo en Inglés | MEDLINE | ID: mdl-16921495

RESUMEN

Previous investigations have suggested that ghrelin, an endogenous orexigenic peptide, is involved in the pathology of eating disorders. We conducted a study to determine whether any preproghrelin gene polymorphisms are associated with eating disorders. Three hundred thirty-six eating disorder patients, including 131 anorexia nervosa (AN)-restricting types (AN-R), 97 AN-binge eating/purging types (AN-BP) and 108 bulimia nervosa (BN)-purging types (BN-P), and 300 healthy control subjects participated in the study. Genotyping was performed to determine the polymorphisms present, and with this information, linkage disequilibrium (LD) between the markers was analyzed and the distributions of the genotypes, the allele frequencies, and the haplotype frequencies were compared between the groups. The Leu72Met (408 C > A) (rs696217) polymorphism in exon 2 and the 3056 T > C (rs2075356) polymorphism in intron 2 were in LD (D' = 0.902, r2 = 0.454). Both polymorphisms were significantly associated with BN-P (allele-wise: P = 0.0410, odds ratio (OR) = 1.48; P = 0.0035, OR = 1.63, for Leu72Met and 3056 T > C, respectively). In addition, we observed a significant increase in the frequency of the haplotype Met72-3056C in BN-P patients (P = 0.0059, OR = 1.71). Our findings suggest that the Leu72Met (408 C > A) and the 3056 T > C polymorphisms of the preproghrelin gene are associated with susceptibility to BN-P.


Asunto(s)
Bulimia Nerviosa/genética , Predisposición Genética a la Enfermedad/genética , Hormonas Peptídicas/genética , Polimorfismo de Nucleótido Simple/genética , Adulto , Femenino , Frecuencia de los Genes , Genotipo , Ghrelina , Haplotipos/genética , Humanos , Desequilibrio de Ligamiento
17.
Psychiatr Genet ; 16(2): 49-50, 2006 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16538178

RESUMEN

Lithium is a first-line agent for the treatment of bipolar disorder. A significant association between the Val66Met polymorphism of the brain-derived neurotrophic factor gene and bipolar disorder has been reported. We investigated whether this polymorphism is associated with the response to lithium treatment in Japanese patients with bipolar disorder. Patients had been treated with lithium carbonate for more than 1 year, and the response was retrospectively evaluated. No significant differences were found in the genotype distribution or allele frequency between responders and non-responders. Our results suggested that the brain-derived neurotrophic factor Val66Met polymorphism might not greatly contribute to the efficacy of lithium in bipolar disorder.


Asunto(s)
Antimaníacos/farmacocinética , Trastorno Bipolar/genética , Factor Neurotrófico Derivado del Encéfalo/genética , Resistencia a Medicamentos/genética , Carbonato de Litio/farmacocinética , Polimorfismo de Nucleótido Simple , Adulto , Alelos , Sustitución de Aminoácidos , Antimaníacos/uso terapéutico , Trastorno Bipolar/tratamiento farmacológico , Factor Neurotrófico Derivado del Encéfalo/fisiología , Femenino , Frecuencia de los Genes , Genotipo , Humanos , Japón , Carbonato de Litio/uso terapéutico , Masculino , Persona de Mediana Edad , Estudios Retrospectivos
18.
Schizophr Res ; 83(2-3): 179-83, 2006 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16504480

RESUMEN

It has been reported that expression of the chromogranin A (CHGA) gene is reduced in the prefrontal cortex and cerebrospinal fluid of patients with schizophrenia. Single-marker and haplotype analyses of SNPs within the CHGA gene were performed in 633 subjects with schizophrenia and 589 healthy controls. A significant association with schizophrenia was observed to one SNP marker, rs9658635 (p=0.0269), and with a 2 marker haplotype (p=0.0016). Significant association of rs9658635 was then replicated in a second independent cohort (377 schizophrenia and 338 control samples) (p=0.007). These results suggest that the CHGA gene is associated with the risk of developing schizophrenia in the Japanese population.


Asunto(s)
Cromograninas/genética , Predisposición Genética a la Enfermedad , Polimorfismo Genético/genética , Esquizofrenia/genética , Adulto , Estudios de Casos y Controles , Cromogranina A , Femenino , Frecuencia de los Genes , Genotipo , Humanos , Japón/epidemiología , Masculino , Persona de Mediana Edad , Esquizofrenia/epidemiología , Análisis de Secuencia
19.
Schizophr Res ; 82(2-3): 185-9, 2006 Feb 28.
Artículo en Inglés | MEDLINE | ID: mdl-16442780

RESUMEN

Several investigations suggest that complexin may be a schizophrenia-susceptibility factor. We conducted a genetic association analysis between complexin genes (CPLX1 and CPLX2) and schizophrenia in Japanese patients (377 cases and 341 controls). Ten and eleven haplotype-tagging (ht)SNPs in CPLX1 and CPLX2, respectively, were selected. Only one htSNP (rs930047 in CPLX2) in allele-wise analysis showed significance, and even this disappeared with an increased sample size (563 cases and 519 controls: P = .757). Haplotype-wise analysis showed a weak association with a combination of htSNPs in CPLX2 (P = .0424), but this may be a result of type I error due to multiple testing. Our results suggest that complexin genes do not play a major role in schizophrenia in Japanese patients.


Asunto(s)
Pueblo Asiatico/genética , Proteínas del Tejido Nervioso/genética , Esquizofrenia/genética , Proteínas Adaptadoras del Transporte Vesicular , Adulto , Alelos , Femenino , Expresión Génica/fisiología , Predisposición Genética a la Enfermedad/genética , Genotipo , Haplotipos , Humanos , Desequilibrio de Ligamiento , Masculino , Persona de Mediana Edad , Polimorfismo de Nucleótido Simple , Esquizofrenia/diagnóstico , Estadística como Asunto
20.
Neuropsychopharmacology ; 31(4): 866-71, 2006 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16192982

RESUMEN

Several lines of evidence suggest that abnormalities in the serotonin system may be related to the pathophysiology of schizophrenia. The 5-HT7 receptor is considered to be a possible schizophrenia-susceptibility factor, based on findings from binding, animal, postmortem, and genomewide linkage studies. In this study, we conducted linkage disequilibrium (LD) mapping of the human 5-HT7 receptor gene (HTR7) and selected four 'haplotype-tagging (ht) SNPs'. Using these four htSNPs, we then conducted an LD case-control association analysis in 383 Japanese schizophrenia patients and 351 controls. Two htSNPs (SNP2 and SNP5) and haplotypes were found to be associated with schizophrenia. A promoter SNP (SNP2) was further assessed in a dual-luciferase reporter assay, but it was not found to have any functional relevance. Although we failed to find an actual susceptibility variant that could modify the function of HTR7, our results support the supposition that HTR7 is a susceptibility gene for schizophrenia in this ethnic group.


Asunto(s)
Predisposición Genética a la Enfermedad , Polimorfismo de Nucleótido Simple/genética , Receptores de Serotonina/genética , Esquizofrenia/genética , Adulto , Estudios de Casos y Controles , Análisis Mutacional de ADN , Femenino , Frecuencia de los Genes , Genotipo , Humanos , Japón/epidemiología , Masculino , Persona de Mediana Edad , Esquizofrenia/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA